Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > PwC sees continuation of US$ 5 to 15 Billion Bio M&A Deals

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Aug 24, 2024 12:14pm

70 Views

Post# 36194660

RE:RE:RE:RE:PwC sees continuation of US$ 5 to 15 Billion Bio M&A Deals

June 2024 - PwC - Germany - M&A will continue to be a critical tool to unlock value and drive innovation across health industries as dealmakers gear up for a busy second half of 2024.

" .....large pharmaceutical companies will continue to pursue biotech targets and products that can offset revenue declines from lost exclusivity in the coming years. Large companies continue to explore divestitures of select products or business units to enhance the growth prospects of their remaining portfolios....."

Biotech acquisitions to fend off patent cliffs: Large-cap pharmaceutical companies will continue to face patent cliffs and gaps in their pipelines in the latter half of this decade and will look for M&A opportunities to achieve their growth plans. Small and midsize biotech companies that can fill pipeline gaps in the second half of the decade will receive significant attention in 2024.

https://www.pwc.com/gx/en/services/deals/trends/health-industries.html